A therapeutic confirmatory study to assess the safety and efficacy of Zydena® (Udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus

Du Geon Moon, Dae Yul Yang, Choong Hyun Lee, Tai Young Ahn, Kweon Sik Min, Kwangsung Park, Jong Kwan Park, Je-Jong Kim

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Introduction. Patients with diabetes mellitus (DM) are reported to experience more severe erectile dysfunction (ED) symptoms and respond less to ED treatments compared with patients with ED of other etiologies. Aim. This study was undertaken to evaluate the safety and efficacy of udenafil for the treatment of ED in a larger number of patients with DM. Methods. A placebo-controlled, randomized, double-blind, double-dummy, parallel-group design multicenter study, fixed-dose trial was conducted. The trial involved seven study sites in Korea, with 174 ED patients with DM. The subjects, treated with placebo, 100mg, or 200mg of udenafil for 12 weeks, were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Question (GAQ) during the study period. Main Outcome Measures. The primary efficacy parameter was the change in the erectile function domain (EFD) score of IIEF from baseline. Secondary parameters were IIEF questions 3 (Q3) and Q4, SEP Q2 and Q3, rate of achieving normal erectile function (EFD≥26), and the response to GAQ. Results. Compared with the placebo, patients receiving both doses of udenafil showed statistically significant improvements in the IIEF-EFD score, respectively. However, statistically significant difference was not observed between the udenafil 100mg and the udenafil 200mg groups. Similar results were observed in the comparison of Q3 and Q4 of IIEF, SEP diary, and GAQ. The percentages of subjects experiencing at least one adverse event related to the study drugs were 3.6%, 15.8%, and 22.4% for the placebo, udenafil 100mg, and udenafil 200mg groups, respectively. However, these events were all mild in severity. Major adverse events were flushing, headache, nausea, and conjunctival hyperemia. Conclusion. Udenafil was significantly effective for the treatment of ED, demonstrating statistically significant improvement in erectile function in patients with DM. The incidence of adverse events was relatively low and well tolerated in patients with DM.

Original languageEnglish
Pages (from-to)2048-2061
Number of pages14
JournalJournal of Sexual Medicine
Volume8
Issue number7
DOIs
Publication statusPublished - 2011 Jan 1

Fingerprint

udenafil
Erectile Dysfunction
Diabetes Mellitus
Safety
Placebos
Therapeutics
Hyperemia
Korea

Keywords

  • Diabetes mellitus
  • Erectile dysfunction
  • Pharmacotherapy for erectile dysfunction in men with diabetes
  • Udenafil

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology
  • Urology

Cite this

A therapeutic confirmatory study to assess the safety and efficacy of Zydena® (Udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus. / Moon, Du Geon; Yang, Dae Yul; Lee, Choong Hyun; Ahn, Tai Young; Min, Kweon Sik; Park, Kwangsung; Park, Jong Kwan; Kim, Je-Jong.

In: Journal of Sexual Medicine, Vol. 8, No. 7, 01.01.2011, p. 2048-2061.

Research output: Contribution to journalArticle

Moon, Du Geon ; Yang, Dae Yul ; Lee, Choong Hyun ; Ahn, Tai Young ; Min, Kweon Sik ; Park, Kwangsung ; Park, Jong Kwan ; Kim, Je-Jong. / A therapeutic confirmatory study to assess the safety and efficacy of Zydena® (Udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus. In: Journal of Sexual Medicine. 2011 ; Vol. 8, No. 7. pp. 2048-2061.
@article{867e9bb62d314b96a49baf6957ca7d40,
title = "A therapeutic confirmatory study to assess the safety and efficacy of Zydena{\circledR} (Udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus",
abstract = "Introduction. Patients with diabetes mellitus (DM) are reported to experience more severe erectile dysfunction (ED) symptoms and respond less to ED treatments compared with patients with ED of other etiologies. Aim. This study was undertaken to evaluate the safety and efficacy of udenafil for the treatment of ED in a larger number of patients with DM. Methods. A placebo-controlled, randomized, double-blind, double-dummy, parallel-group design multicenter study, fixed-dose trial was conducted. The trial involved seven study sites in Korea, with 174 ED patients with DM. The subjects, treated with placebo, 100mg, or 200mg of udenafil for 12 weeks, were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Question (GAQ) during the study period. Main Outcome Measures. The primary efficacy parameter was the change in the erectile function domain (EFD) score of IIEF from baseline. Secondary parameters were IIEF questions 3 (Q3) and Q4, SEP Q2 and Q3, rate of achieving normal erectile function (EFD≥26), and the response to GAQ. Results. Compared with the placebo, patients receiving both doses of udenafil showed statistically significant improvements in the IIEF-EFD score, respectively. However, statistically significant difference was not observed between the udenafil 100mg and the udenafil 200mg groups. Similar results were observed in the comparison of Q3 and Q4 of IIEF, SEP diary, and GAQ. The percentages of subjects experiencing at least one adverse event related to the study drugs were 3.6{\%}, 15.8{\%}, and 22.4{\%} for the placebo, udenafil 100mg, and udenafil 200mg groups, respectively. However, these events were all mild in severity. Major adverse events were flushing, headache, nausea, and conjunctival hyperemia. Conclusion. Udenafil was significantly effective for the treatment of ED, demonstrating statistically significant improvement in erectile function in patients with DM. The incidence of adverse events was relatively low and well tolerated in patients with DM.",
keywords = "Diabetes mellitus, Erectile dysfunction, Pharmacotherapy for erectile dysfunction in men with diabetes, Udenafil",
author = "Moon, {Du Geon} and Yang, {Dae Yul} and Lee, {Choong Hyun} and Ahn, {Tai Young} and Min, {Kweon Sik} and Kwangsung Park and Park, {Jong Kwan} and Je-Jong Kim",
year = "2011",
month = "1",
day = "1",
doi = "10.1111/j.1743-6109.2011.02268.x",
language = "English",
volume = "8",
pages = "2048--2061",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - A therapeutic confirmatory study to assess the safety and efficacy of Zydena® (Udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus

AU - Moon, Du Geon

AU - Yang, Dae Yul

AU - Lee, Choong Hyun

AU - Ahn, Tai Young

AU - Min, Kweon Sik

AU - Park, Kwangsung

AU - Park, Jong Kwan

AU - Kim, Je-Jong

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Introduction. Patients with diabetes mellitus (DM) are reported to experience more severe erectile dysfunction (ED) symptoms and respond less to ED treatments compared with patients with ED of other etiologies. Aim. This study was undertaken to evaluate the safety and efficacy of udenafil for the treatment of ED in a larger number of patients with DM. Methods. A placebo-controlled, randomized, double-blind, double-dummy, parallel-group design multicenter study, fixed-dose trial was conducted. The trial involved seven study sites in Korea, with 174 ED patients with DM. The subjects, treated with placebo, 100mg, or 200mg of udenafil for 12 weeks, were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Question (GAQ) during the study period. Main Outcome Measures. The primary efficacy parameter was the change in the erectile function domain (EFD) score of IIEF from baseline. Secondary parameters were IIEF questions 3 (Q3) and Q4, SEP Q2 and Q3, rate of achieving normal erectile function (EFD≥26), and the response to GAQ. Results. Compared with the placebo, patients receiving both doses of udenafil showed statistically significant improvements in the IIEF-EFD score, respectively. However, statistically significant difference was not observed between the udenafil 100mg and the udenafil 200mg groups. Similar results were observed in the comparison of Q3 and Q4 of IIEF, SEP diary, and GAQ. The percentages of subjects experiencing at least one adverse event related to the study drugs were 3.6%, 15.8%, and 22.4% for the placebo, udenafil 100mg, and udenafil 200mg groups, respectively. However, these events were all mild in severity. Major adverse events were flushing, headache, nausea, and conjunctival hyperemia. Conclusion. Udenafil was significantly effective for the treatment of ED, demonstrating statistically significant improvement in erectile function in patients with DM. The incidence of adverse events was relatively low and well tolerated in patients with DM.

AB - Introduction. Patients with diabetes mellitus (DM) are reported to experience more severe erectile dysfunction (ED) symptoms and respond less to ED treatments compared with patients with ED of other etiologies. Aim. This study was undertaken to evaluate the safety and efficacy of udenafil for the treatment of ED in a larger number of patients with DM. Methods. A placebo-controlled, randomized, double-blind, double-dummy, parallel-group design multicenter study, fixed-dose trial was conducted. The trial involved seven study sites in Korea, with 174 ED patients with DM. The subjects, treated with placebo, 100mg, or 200mg of udenafil for 12 weeks, were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Question (GAQ) during the study period. Main Outcome Measures. The primary efficacy parameter was the change in the erectile function domain (EFD) score of IIEF from baseline. Secondary parameters were IIEF questions 3 (Q3) and Q4, SEP Q2 and Q3, rate of achieving normal erectile function (EFD≥26), and the response to GAQ. Results. Compared with the placebo, patients receiving both doses of udenafil showed statistically significant improvements in the IIEF-EFD score, respectively. However, statistically significant difference was not observed between the udenafil 100mg and the udenafil 200mg groups. Similar results were observed in the comparison of Q3 and Q4 of IIEF, SEP diary, and GAQ. The percentages of subjects experiencing at least one adverse event related to the study drugs were 3.6%, 15.8%, and 22.4% for the placebo, udenafil 100mg, and udenafil 200mg groups, respectively. However, these events were all mild in severity. Major adverse events were flushing, headache, nausea, and conjunctival hyperemia. Conclusion. Udenafil was significantly effective for the treatment of ED, demonstrating statistically significant improvement in erectile function in patients with DM. The incidence of adverse events was relatively low and well tolerated in patients with DM.

KW - Diabetes mellitus

KW - Erectile dysfunction

KW - Pharmacotherapy for erectile dysfunction in men with diabetes

KW - Udenafil

UR - http://www.scopus.com/inward/record.url?scp=79960467698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960467698&partnerID=8YFLogxK

U2 - 10.1111/j.1743-6109.2011.02268.x

DO - 10.1111/j.1743-6109.2011.02268.x

M3 - Article

C2 - 21554549

AN - SCOPUS:79960467698

VL - 8

SP - 2048

EP - 2061

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 7

ER -